Evaluation of Cladribine treatment in refractory celiac disease type Ⅱ  

作　　者：Greetje J Tack Wieke HM Verbeek Abdul Al-Toma Dirk J Kuik Marco WJ Schreurs Otto Visser Chris JJ Mulder 

机构地区：[1]Department of Gastroenterology and Hepatology, VU University Medical Center [2]Department of Gastroenterology and Hepatology, St. Antonius Hospital [3]Department of Epidemiology and Biostatistics, VU University Medical Center [4]Department of Pathology, VU University Medical Center [5]Department of Haematology, VU University Medical Center

出　　处：《World Journal of Gastroenterology》2011年第4期506-513,共8页世界胃肠病学杂志（英文版）

基　　金：Supported by An Unrestricted Grant from Astra Zeneca

摘　　要：AIM: To evaluate cladribine [2-chlorodeoxyadenosine (2-CdA)] therapy in refractory celiac disease (RCD) Ⅱ. METHODS: An open-label cohort-study of RCD Ⅱ patients treated with 2-CdA was performed between 2000 and 2010. Survival rate, enteropathy associated T-cell lymphoma (EATL) occurrence, clinical course, and histological and immunological response rates were evaluated. RESULTS: Overall, 32 patients were included with a median follow-up of 31 mo. Eighteen patients responded well to 2-CdA. Patients responsive to 2-CdA had a statistically significant increased survival compared to those who were unresponsive. The overall 3- and 5-year survival was 83% in the responder and 63% and 22% in the non-responder group, respectively. The overall 2-year clinical, histological and immunological response rates were 81%, 47% and 41%, respectively. Progression into EATL was reported in 16%, all of these patients died. CONCLUSION: Treatment of RCD Ⅱ with 2-CdA holds promise, showing excellent clinical and histological response rates, and probably less frequent transition into EATL.AIM： To evaluate cladribine [2-chlorodeoxyadenosine （2-CdA）] therapy in refractory celiac disease （RCD） Ⅱ. METHODS： An open-label cohort-study of RCD Ⅱ patients treated with 2-CdA was performed between 2000 and 2010. Survival rate, enteropathy associated T-cell lymphoma （EATL） occurrence, clinical course, and histological and immunological response rates were evaluated. RESULTS： Overall, 32 patients were included with a median follow-up of 31 mo. Eighteen patients responded well to 2-CdA. Patients responsive to 2-CdA had a statistically significant increased survival compared to those who were unresponsive. The overall 3- and 5-year survival was 83% in the responder and 63% and 22% in the non-responder group, respectively. The overall 2-year clinical, histological and immunological response rates were 81%, 47% and 41%, respectively. Progression into EATL was reported in 16%, all of these patients died. CONCLUSION： Treatment of RCD Ⅱ with 2-CdA holds promise, showing excellent clinical and histological response rates, and probably less frequent transition into EATL.

关 键 词：CLADRIBINE Refractory celiac disease Clinical course Enteropathy associated T-cell lymphoma SURVIVAL 

分 类 号：R57[医药卫生—消化系统]